

We claim:

1. A combination comprising a drug that blocks 5-HT-2A receptors, a drug that blocks D2 receptors, and a drug that blocks dopamine reuptake, wherein the drug that blocks 5-HT-2A receptors, the drug that blocks D2 receptors, and the drug that blocks dopamine reuptake together comprise a therapeutically effective amount of the drug that blocks 5-HT-2A receptors, the drug that blocks D2 receptors, and the drug that blocks dopamine reuptake.
2. The combination of claim 1, wherein the drug that blocks 5-HT-2A receptors is a 5-HT-2A antagonist.
3. The combination of claim 1, wherein the drug that blocks D2 receptors is a D2 antagonist.
4. The combination of claim 1, wherein the drug that blocks dopamine reuptake is a dopamine transporter blocker.
5. The combination of claim 1, wherein the combination is a single dosage form.
6. The combination of claim 1, wherein one drug blocks 5-HT-2A receptors, blocks D2 receptors, and blocks dopamine reuptake.
7. The combination of claim 1, wherein a first drug blocks 5-HT-2A receptors and blocks D2 receptors, and a second drug blocks dopamine reuptake.
8. The combination of claim 1, wherein a first drug blocks 5-HT-2A receptors and blocks dopamine reuptake, and a second drug blocks D2 receptors.
9. The combination of claim 1, wherein a first drug blocks D2 receptors, and blocks dopamine reuptake, and a second drug blocks 5-HT-2A receptors.
10. A method of treating schizophrenia in a subject comprising administration to the

subject a combination comprising a drug that blocks 5-HT-2A receptors, a drug that blocks D2 receptors, and a drug that blocks dopamine reuptake, wherein the drug that blocks 5-HT-2A receptors, the drug that blocks D2 receptors, and the drug that blocks dopamine reuptake together comprise a therapeutically effective amount of the drug that blocks 5-HT-2A receptors, the drug that blocks D2 receptors, and a the drug that blocks dopamine reuptake.

11. The method of treating a subject of claim 10, wherein the administration of each of the drug that blocks 5-HT-2A receptors, the drug that blocks D2 receptors, and the drug that blocks dopamine reuptake occurs sequentially within about 24 hours.
12. The method of treating a subject of claim 10, wherein the administration of each of the drug that blocks 5-HT-2A receptors, the drug that blocks D2 receptors, and the drug that blocks dopamine reuptake occurs sequentially within about 12 hours.
13. The method of treating a subject of claim 10, wherein the administration of each of the drug that blocks 5-HT-2A receptors, the drug that blocks D2 receptors, and the drug that blocks dopamine reuptake occurs sequentially within about 6 hours.
14. The method of treating a subject of claim 10, wherein the administration of each of the drug that blocks 5-HT-2A receptors, the drug that blocks D2 receptors, and the drug that blocks dopamine reuptake occurs sequentially within about 3 hours.
15. The method of treating a subject of claim 10, wherein the administration of each of the drug that blocks 5-HT-2A receptors, the drug that blocks D2 receptors, and the drug that blocks dopamine reuptake occurs sequentially within about 1 hour.
16. The method of treating a subject of claim 10, wherein the administration of each of the drug that blocks 5-HT-2A receptors, the drug that blocks D2 receptors, and

a the drug that blocks dopamine reuptake occurs substantially concomitantly.

17. The method of treating a subject of claim 10, wherein one drug blocks 5-HT-2A receptors, blocks D2 receptors, and blocks dopamine reuptake.

5 18. The method of treating a subject of claim 10, wherein a first drug blocks 5-HT-2A receptors and blocks D2 receptors, and a second drug blocks dopamine reuptake.

19. The method of treating a subject of claim 10, wherein a first drug blocks 5-HT-2A receptors and blocks dopamine reuptake, and a second drug blocks D2 receptors.

10 20. The method of treating a subject of claim 10, wherein a first drug blocks D2 receptors, and blocks dopamine reuptake, and a second drug blocks 5-HT-2A receptors.

21. A method of treating schizophrenia in a subject comprising blocking 5-HT-2A receptors, blocking D2 receptors, and inhibiting dopamine reuptake in a subject in need thereof.

15